Chromosome 7 abnormalities in prostate cancer detected by dual-color fluorescence in situ hybridization

Cancer Genetics and Cytogenetics

Volumn 107, Issue 1, 1998, Pages 51-60

  Cui, Jiang ^a   Deubler, Debra A ^a   Rohr, L Ralph ^a   Zhu, Xiao Lin ^a   Maxwell, Teresa M ^a   Changus, James E ^b   Brothman, Arthur R ^a,c  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b JFK Medical Center   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; CANCER GENETICS; CHROMOSOME 7Q; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; MALE; NUMERICAL CHROMOSOME ABERRATION; PRIORITY JOURNAL; PROSTATE CANCER; TETRASOMY; TRISOMY; TUMOR SUPPRESSOR GENE;

ANEUPLOIDY; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 7; GENETIC MARKERS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; PARAFFIN EMBEDDING; PROSTATIC NEOPLASMS; X CHROMOSOME;

BACTERIA (MICROORGANISMS);

EID: 0032213757     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(98)00074-0     Document Type: Article

References (40)

1. 1. Landis SH, Murray T, Bolden S, Wingo PA (1998): Cancer statistics, 1998. CA-A Cancer J Clinicians 48:6-29.
2. 2. Sandberg AA (1992): Chromosomal abnormalities and related events in prostate cancer. Human Pathol 23:368-380.
3. 3. Brothman AR, Williams BJ (1996): Prostate cancer. In: Cytogenetics Cancer Markers. SR Wolman, S Sell, eds. Humana Press Inc., Totowa, pp. 223-246.
4. 4. Kallioniemi O, Visakorpi T (1996): Genetic basis and clonal evolution of human prostate cancer. Adv Cancer Res 68:225-255.
5. 5. Brothman AR, Peehl DM, Petal AM, McNeal JE (1990): Frequency and pattern of karyotypic abnormalities in human prostate cancer. Cancer Res 50:3795-3803.
6. 6. Lundgren R, Mandahl N, Heim S, Limon J, Henrikson H, Mitelman F (1992): Cytogenetic analysis of 57 primary prostate adenocarcinomas. Genes Chromosom Cancer 4:16-24.
7. 7. Atkin NB, Baker MC (1993): Chromosome 7q deletions: observations on 13 malignant tumors. Cancer Genet Cytogent 67:123-125.
8. 8. Lukeis R, Ball D, Irving L, Garson OM, Hasthorpe S (1993): Chromosome abnormalities in non-small cell lung cancer pleural effusions: Cytogenetic indicators of disease subgroups. Genes Chromosom Cancer 8:262-269.
9. 9. Kibbelaar RE, Mulder JWR, Dreef EJ, van-Kamp H, Fibbe WE, Wessels JW, Beverstock GC, Haak HL, Kluin PM (1993): Detection of monosomy 7 and trisomy 8 in myeloid neoplasia: A comparison of banding and fluorescence in situ hybridization. Blood 82:904-913.
10. 10. Zenklusen JC, Thompson JC, Troncoso P, Kagan J, Conti CJ (1994): Loss of heterozygosity in human primary prostate carcinomas: a possible tumor suppressor gene at 7q31.1. Cancer Res 54:6370-6373.
11. 11. Takahashi S, Shan AL, Ritland SR, Dalacey KA, Bostwik DG, Lieber MM, Thibodeau SN, Jenkins RB (1995): Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression. Cancer Res 55:4114-4119.
12. 12. Zenklusen JC, Bieche I, Lidereau R, Conti CJ (1994): (C-A)n microsatellite repeat D7S522 is the most commonly deleted region in human primary breast cancer. Proc Natl Acad Sci USA 91:12155-12158.
13. 13. Zenklusen JC, Thompson JC, Klein-Szanto AJP, Conti CJ (1995): Frequent loss of heterozygosity in human primary squamous cell and colon carcinomas at 7q31.1: evidence for a broad range tumor suppressor gene. Cancer Res 55:1347-1350.
14. 14. Kuniyasu H, Yasui W, Yokazaki H, Akagi M, Akama Y, Kitahara K, Fujii K, Tahara E (1994): Frequent loss of heterozygosity of the long arm of chromosome 7 is closely associated with progression of human gastric carcinomas. Int J Cancer 59:597-600.
15. 15. Achille A, Biasi MO, Zamboni G, Bogina G, Magalini AR, Pederzoli P, Perucho M, Scarpa A (1994): Chromosome 7q allelic losses in pancreatic carcinoma. Cancer Res 56:3808-3813.
16. 16. Jenkins RB, Takahashi S, Delacey K, Bergstralh E, Lieher M (1998): Prognostic significance of allelic imbalance of chromosome arms 7q, 8p, 16q, and 18q in stage T3N0M0 prostate cancer. Genes Chromosom Cancer 21:131-143.
17. 17. Johansson B, Heim S, Mandahl N, Mertens F, Mitelman F (1993): Trisomy 7 in nonneoplastic cells. Genes Chromosom Cancer 6:199-205.
18. 18. Persons DL, Gibney DJ, Katzmann JA, Lieber MM, Farrow GM, Jenkins RB (1993): Use of fluorescence in situ hybridization for deoxyribonucleic acid ploidy analysis of prostatic adenocarcinoma. J Urol 150:120-125.
19. 19. Alcaraz A, Takahashi S, Brown JA, Herath JF, Bergstralh EJ, Larson-kelle JJ, Lieber MM, Jenkins RB (1994): Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer. Cancer Res 54:3998-4002.
20. 20. Brown JA, Alcaraz A, Takahashi S, Persons LD, Lieber MM, Jenkins RB (1994): Chromosomal aneusomies detected by fluorescence in situ hybridization (FISH) in clinically localized prostate carcinoma. J Urol 152:1157-1162.
21. 21. Bandyk MG, Zhao L, Troncoso P, Pisters LL, Palmer JL, von-Eschenbach AC, Chung LWK, Liang JC (1994): Trisomy 7: a potential cytogenetic marker of human prostate cancer progression. Genes Chromosom Cancer 9:19-27.
22. 22. Jones E, Zhu XL, Rohr LR, Stephenson RA, Brothman AR (1994): Aneusomy of chromosome 7 and 17 detected by FISH in prostate cancer and the effects of selection in vitro. Genes Chromosom Center 11:163-170.
23. 23. Takahashi S, Qian J, Brown JA, Alcaraz A, Bostwick DG, Lieber MM, Jenkins RB (1994): Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies. Cancer Res 54:3574-3579.
24. 24. Visakorpi T, Kallioniemi S, Syvanen A, Hyytinen ER, Karhu R, Tammela T, Isola JJ, Kallioniemi O (1995): Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 55:342-347.
25. 25. Ekstrand AJ, James CD, Cavenne WK, Seliger B, Pettersson RF, Collins VP (1991): Genes for epidermal-grow-factor-receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51:2164-2172.
26. 26. Santer G, Haley J, Chew K, Kerschmann R, Moore D, Carroll P, Moch H, Gudat F, Mithatsch MJ, Waldman F (1994): Epidermal-growth-factor receptor expression is associated with rapid tumor proliferation in bladder cancer. Int J Cancer 57:508-514.
27. 27. Maddy SQ, Chrisholm GD, Busuttil A, Habib FK (1989): Epidermal growth factor receptors in human prostate cancer: correlation with histological differentiation of the tumor. Br J Cancer 60:41-44.
28. 28. Morris GL, Dodd JG (1990): Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines. J Urol 143:1272-1274.
29. 29. Turkeri LN, Sakr WA, Wykes SM, Grignon DJ, Pontes HE, Macoska JA (1994): Comparative analysis of epidermal growth factor receptor gene expression protein product in benign, premalignant, and malignant prostate tissue. Prostate 25:199-205.
30. 30. Gleason DF, Nellinger GT, Veterans Administrative Cooperative Urological Research Group (1974): Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111:58-64.
31. 31. Deubler DA, Williams BJ, Zhu XL, Steele MR, Rohr LR, Jensen JC, Stephenson RA, Changus JE, Miller GJ, Becich MJ, Brothman AR (1997): Allelic loss detected on chromosome 8, 10 and 17 by FISH using single-copy P1 probes on isolated nuclei from paraffin-embedded prostate tumors. Am J Pathol 150:841-850.
32. 32. Maniatis T, Fritsch EF, Sambrock J (1982): Molecular Cloning. A Laboratory Manual. Cold Spring Harbor Laboratory, New York, pp. 86-96.
33. 33. Williams BJ, Jones E, Zhu XL, Steele MR, Stephenson RA, Rohr LR, Brothman AR. (1995): Evidence of a tumor suppressor gene distal to BRCA1 in prostate cancer. J Urol 155:720-725.
34. 34. Qian J, Bostwich DG, Takahashi S, Borell TJ, Brown JA, Lieber MM, Jenkins RB (1996): Comparison of fluorescence on situ hybridization analysis of isolated nuclei and routine histological sections from paraffin-embedded prostatic adenocarcinoma specimens. Am J Pathol 149:1193-1199.
35. 35. Huang S, Xiao S, Renchaw AA, Loughlin KR, Hudson TJ, Fletcher JA (1996): Fluorescence in situ hybridization evaluation of chromosome deletion patterns in prostate cancer. Am J Pathology 149:1566-1573.
36. 36. Visakorpi T, Kallionemi OP, Koivula T, Harvey J, Isola J (1992): Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas. Modern Pathol 5:643-648.
37. 37. Maygarden SJ, Strom S, Ware JL (1992): Localization of epidermal growth factor receptor by immunochemical methods in human prostatic carcinoma, prostatic intraepithelial neoplasia, and benign hyperplasia. Arch Pathol Lab Med 115:269-273.
38. 38. Mellon K, Thompson S, Charlton RG, March C, Robinson M, Lane DP, Harris AL, Home CHW, Neal DE (1992): p53, c-erB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J Urol 147:496-499.
39. 39. Jenkins RB, Qian J, Lee HK, Huang H, Hirasawa K, Bostwick DG, Proffitt J, Wilber K, Lieber MM, Liu W, Smith DI (1998): A molecular cytogenetic analysis of 7q31 in prostate cancer. Cancer Res 58:759-766.
40. 40. Huang H, Qian J, Jenkins RB, Smith D (1998): FISH mapping of YAC clones at human chromosomal band 7q31.2: identification of YACS spanning FRA7G within the common region of LOH in breast and prostate cancer. Gene Chromosom Cancer 21:152-159.